Our molecular genetic studies of the pivotal cyclin G1 (CCNG1) oncogene—conducted in the crucible of clinical oncology and analyzed in the context of intractable end-stage metastatic disease—provide new insights into the proximal and accessible Cyclin-G1/Cdk/Myc/Mdm2/p53 Axis of cell cycle activation and sustained cancer cell survival: revealing key “competence factors” and stem cell survival pathways, while identifying the cyclin G1 (CCNG1) oncogene as a strategic locus and clinical target for metastatic cancer control (Kim et al., 2017; Al-Shihabi et al., 2018; Gordon et al., 2018). This evidence concerns the gene MYC and metastatic neoplasm.